← Back to patent-cliff list
Chlorine dioxide (Tarsus Pharmaceuticals)
Tier C — Watch / tradeChlorine dioxide (Tarsus Pharmaceuticals)
iRenix Medical Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Updating
Indications (approved)：视网膜病变, Glaucoma, 视网膜静脉阻塞, Diabetic macular oedema
Regional status
US
Phase III
2021-11-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Chlorine dioxide (Tarsus Pharmaceuticals)?
Approved indications include: 视网膜病变, Glaucoma, 视网膜静脉阻塞, Diabetic macular oedema.
When does the Chlorine dioxide (Tarsus Pharmaceuticals) patent expire?
No public expiry year is available for Chlorine dioxide (Tarsus Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Chlorine dioxide (Tarsus Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21